title: Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy.
abstract: BACKGROUND
  C1-inhibitor (C1-INH) is a serine protease inhibitor regulating the complement, kinin-kallikrein, coagulation, and fibrinolytic systems. Hereditary angioedema (HAE) is caused by an inherited deficiency of C1-INH characterized by sudden, recurrent edematous swellings of the subcutaneous or submucosal tissues. The optional therapy for the acute management of HAE is administration of human C1-INH (hC1-INH) concentrate. However, hC1-INH is not available in many countries, in which case fresh frozen plasma is an alternative.
  
  
  OBJECTIVE
  To summarize our experience with hC1-INH concentrate in patients with HAE.
  
  
  METHODS
  Clinical and laboratory information on the effectiveness and safety of hC1-INH administered to relieve 468 acute edematous attacks in 61 patients with HAE was analyzed.
  
  
  RESULTS
  Severe abdominal or subcutaneous attacks and laryngeal edema were consistently relieved by the administration of 500 U hC1-INH concentrate. Symptoms improved within 15 to 60 minutes of administration. Progression of the attacks was never observed, and there were no recurrent attacks within 72 hours. hC1-INH concentrate requirements did not change after repeated use. hC1-INH concentrate proved effective in the management of 94 attacks in 22 children and 6 attacks in 4 pregnant women. Adverse reactions, viral infections, and antibody formation against the purified protein did not occur.
  
  
  CONCLUSIONS
  The administration of hC1-INH concentrate in HAE is highly effective and safe for the treatment of acute attacks and short-term prophylaxis and in pediatric patients and pregnant women.
  
  
  CONCLUSIONS
  Human C1-INH concentrate is effective and safe for the treatment of acute HAE attacks as well as for short-term prophylaxis.
authors.affiliation: Semmelweis University, Faculty of Medicine, 3rd Department of Internal Medicine, Budapest, Hungary. farkash@kut.sote.hu
authors.forename: Henriette
authors.initials: H
authors.lastname: Farkas
authors.forename: László
authors.initials: L
authors.lastname: Jakab
authors.forename: György
authors.initials: G
authors.lastname: Temesszentandrási
authors.forename: Beáta
authors.initials: B
authors.lastname: Visy
authors.forename: György
authors.initials: G
authors.lastname: Harmat
authors.forename: George
authors.initials: G
authors.lastname: Füst
authors.forename: Gábor
authors.initials: G
authors.lastname: Széplaki
authors.forename: Béla
authors.initials: B
authors.lastname: Fekete
authors.forename: István
authors.initials: I
authors.lastname: Karádi
authors.forename: Lilian
authors.initials: L
authors.lastname: Varga
mesh_terms: D000293:Adolescent; D000328:Adult; D000799:Angioedema / Q000188:drug therapy* / Q000235:genetics; D000906:Antibodies / Q000097:blood; D002648:Child; D003174:Complement C1 Inactivator Proteins / Q000009:adverse effects / Q000276:immunology / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged
chemical_list: D000906:Antibodies; D003174:Complement C1 Inactivator Proteins